The TRILINX trial found that adding Xevinapant to local chemoradiation did not improve local control but was associated with a higher rate of distant cancer failures. This counterintuitive outcome highlights the risk of unintended, detrimental systemic effects when developing combination therapies for localized disease.
The TRILINX trial revealed Xevinapant's toxicity was so high that it forced reductions in standard, effective treatments like cisplatin and radiation. This compromised the foundational therapy, leading to worse patient outcomes and demonstrating a key risk in adding novel agents to established regimens.
Xevinapant's Phase III failure, after a promising Phase II trial, was partially attributed to the broader, more heterogeneous patient population. This group experienced greater toxicity than the Phase II cohort, suggesting early-phase safety profiles may not scale, ultimately compromising the efficacy of the entire treatment regimen.